Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics has received U.S. FDA Fast Track Designation for its investigational drug ATH434, aimed at treating Multiple System Atrophy (MSA), a neurodegenerative disease with no approved therapies. This designation, along with positive results from Phase 2 clinical trials, highlights the potential of ATH434 to slow disease progression and improve symptoms, reinforcing the company’s confidence in its MSA program as it prepares for further interactions with the FDA.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. The company is actively engaged in creating innovative therapies to address unmet medical needs, particularly for conditions like Multiple System Atrophy (MSA).
YTD Price Performance: 60.0%
Average Trading Volume: 18,316,003
Technical Sentiment Signal: Sell
Current Market Cap: A$147.3M
See more data about ATH stock on TipRanks’ Stock Analysis page.